Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Multiple-dose, 6-sequence, 3-treatment, 3-period, Crossover Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1018-1 and BR1018-2 in Healthy Adult Subjects

NCT05460364 is registered in ClinicalTrials.gov with Boryung Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT05460364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05460364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Multiple-dose, 6-sequence, 3-treatment, 3-period, Crossover Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1018-1 and BR1018-2 in Healthy Adult Subjects
Lead sponsor
Boryung Pharmaceutical Co., Ltd
Phase
Phase 1
Overall status
Completed
Start date
August 4, 2022
Completion date
October 17, 2022
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hyperlipidemia (e.g., hypercholesterolemia), hypertension